Potential adverse effects of proton pump inhibitors

被引：55

作者：

Coté G.A. ^{[1
]}

Howden C.W. ^{[1
]}

机构：

[1] Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611

来源：

Current Gastroenterology Reports | 2008年 / 10卷 / 3期

关键词：

Omeprazole; Proton Pump Inhibitor; Atrophic Gastritis; Cobalamin; Proton Pump Inhibitor Therapy;

D O I：

10.1007/s11894-008-0045-4

中图分类号：

学科分类号：

摘要：

Proton pump inhibitors (PPIs) have revolutionized the management of gastroesophageal reflux disease and peptic ulcer disease over the past two decades. Among the most commonly prescribed agents worldwide, PPIs' overall safety profile is unquestionable. However, emerging evidence indicates that PPI therapy, particularly with long-term and/or high-dose administration, is associated with several potential adverse effects, including enteric infections (eg, Clostridium difficile), community-acquired pneumonia, and hip fracture, all of which have received much attention recently. We review the current data on these and other potential consequences of PPI therapy. More judicious use of PPIs (eg, administering them in no more than the minimum effective dose to older adult patients) may help to further limit the impact of some of these possible adverse effects. © Springer Science+Business Media, LLC 2008.

引用

页码：208 / 214

页数：6

共 50 条

[1]

Shaheen N.J., Hansen R.A., Morgan D.R., Et al., The burden of gastrointestinal and liver diseases, 2006, Am J Gastroenterol, 101, pp. 2128-2138, (2006)

[2]

Laine L., Ahnen D., McClain C., Et al., Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors, Aliment Pharmacol Ther, 14, pp. 651-668, (2000)

[3]

Hill A.B., The environment and disease: Association or causation?, Proc R Soc Med, 58, pp. 295-300, (1965)

[4]

Thorens J., Froehlich F., Schwizer W., Et al., Bacterial over-growth during treatment with omeprazole compared with cimetidine: A prospective randomised double blind study, Gut, 39, pp. 54-59, (1996)

[5]

Dial S., Alrasadi K., Manoukian C., Et al., Risk of Clostridium difficile diarrhea among hospital impatients prescribed proton pump inhibitors: Cohort and case-control studies, CMAJ, 171, pp. 33-38, (2004)

[6]

Leonard J., Marshall J.K., Moayyedi P., Systematic review of the risk of enteric infection in patients taking acid suppression, Am J Gastroenterol, 102, pp. 2047-2056, (2007)

[7]

Shah S., Lewis A., Leopold D., Et al., Gastric acid suppression does not promote clostridial diarrhoea in the elderly, QJM, 93, pp. 175-181, (2000)

[8]

Loo V.G., Poirier L., Miller M.A., Et al., A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality, N Engl J Med, 353, pp. 2442-2449, (2005)

[9]

Laheij R.J., Sturkenboom M.C., Hassing R.J., Et al., Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs, JAMA, 292, pp. 1955-1960, (2004)

[10]

Gulmez S.E., Holm A., Frederiksen H., Et al., Use of proton pump inhibitors and the risk of community-acquired pneumonia: A population-based case-control study, Arch Intern Med, 167, pp. 950-955, (2007)

← 1 2 3 4 5 →